Quicksilver, Billabong and Volcom stores closing after bankruptcy filing
Three major surf retail stores, Quicksilver, Billabong and Volcom are closing nationwide as the parent company, Liberated Brands filed for bankruptcy earlier this week.
A rise in interest rates, persistent inflation, supply chain delays, a decline in consumer demand, a shift in consumer preferences, and substantial fixed costs were all listed as challenges the company has faced.
As part of court filing documents, Liberated CEO Todd Hymel submitted a 29-page statement detailing "a series of major headwinds and challenges."
The company listed debt of $226 million, with approximately 1,400 employees laid off.
"The Company has been further challenged by trends impacting the retail environment more broadly, including shifting consumer preferences for "fast fashion" and e-commerce as opposed to branded apparel and brick-and-mortar retail," Hymel wrote.
He went on to say that while profits rose during the COVID-19 pandemic as customer demand for outdoor apparel and online shopping spiked, shopping in-person at the stores never fully bounced back.
The brands, rooted in the surf, snow, and skate culture, will continue to produce clothing despite the more than 120 storefront closures.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Portable Oxygen Concentrator Market is expected to double, reaching USD 4.5 billion by 2034
Portable Oxygenerator Market Outlook 2025–2034 Luton, Bedfordshire, United Kingdom, June 10, 2025 (GLOBE NEWSWIRE) -- Market Overview The global portable oxygenerator market is undergoing a period of sustained growth, with an estimated valuation of USD 2.1 billion in 2024. This market is forecasted to expand at a compound annual growth rate (CAGR) of approximately 8.0%, reaching USD 4.5 billion by 2034. The primary drivers of this growth include the increasing prevalence of chronic respiratory diseases such as COPD and asthma, an aging global population, and a rising inclination toward home-based healthcare solutions. Furthermore, technological progress and enhanced accessibility to oxygen therapy devices are transforming the dynamics of the market. Download PDF Brochure: Market Drivers A critical factor contributing to market expansion is the rising burden of respiratory ailments globally. As awareness around chronic lung conditions increases, so does the demand for dependable oxygen therapy equipment. This is especially pronounced among the elderly, who form a significant portion of the patient base requiring portable oxygen delivery systems. Another major driver is the technological evolution of oxygen concentrators. Modern portable oxygenerators are now smaller, lighter, and equipped with longer-lasting batteries, improving their usability for both domestic and mobile purposes. The integration of smart technologies, such as real-time oxygen level monitoring and remote data transmission, has enhanced the effectiveness and attractiveness of these devices. Additionally, healthcare reforms and infrastructure development, particularly in developing countries, are fostering broader adoption of oxygen therapy products. Governments and private players are making significant investments in health systems to accommodate the rising need for respiratory care, thereby opening new market opportunities. Market Restraints and Challenges Despite the optimistic outlook, several obstacles continue to hinder market acceleration. One of the foremost concerns is the high cost of advanced portable oxygenerators, which can deter uptake, especially in low-income or developing regions. While innovations are enhancing functionality, they also often raise the cost of manufacturing and final pricing. Regulatory complexities further impact the industry. Gaining approvals from regulatory bodies can be a time-consuming and expensive process. Moreover, companies face challenges related to distribution logistics, particularly in emerging markets where infrastructure and healthcare access remain limited. Global supply chain disruptions, amplified during the COVID-19 pandemic, revealed vulnerabilities in the procurement and distribution of essential components. Such uncertainties could result in delayed production timelines, reduced inventory levels, and higher operational risks. Segmentation Analysis By Product Type: Continuous Flow vs. Pulse Dose Oxygenerators Portable oxygenerators are broadly classified into continuous flow and pulse dose types. Continuous flow models, which deliver oxygen at a constant rate, dominate the market and are preferred in home care and clinical settings where steady oxygen supply is essential. On the other hand, pulse dose models, which dispense oxygen in bursts synchronized with the user's inhalation, are gaining popularity among mobile users and active individuals due to their energy efficiency and portability. By Technology: Molecular Sieves vs. Membrane Separation In terms of technology, molecular sieve systems lead the market. They are known for delivering high-purity oxygen and are widely adopted in hospital and home care applications. Conversely, membrane separation systems are less efficient but more cost-effective, making them suitable for budget-conscious or recreational applications. Continuous research and development in improving the efficiency and affordability of molecular sieves signal strong growth prospects for this segment. By Application: Medical, Industrial, and Recreational The medical segment remains the dominant application category, accounting for the highest revenue share. This is driven by the clinical need for continuous oxygen therapy among patients with chronic respiratory disorders. However, recreational and industrial applications are emerging steadily. Recreational use, especially in sports and high-altitude activities, is on the rise. In the industrial sector, portable oxygen systems are utilized in manufacturing, welding, and chemical processing, where reliable oxygen delivery in remote environments is crucial. By End-User: Hospitals, Home Care, Emergency Services, and Sports & Fitness Hospitals form the largest user segment, owing to their critical need for oxygen during surgeries, intensive care, and emergency treatments. The home care segment is also expanding rapidly due to the aging population and a societal shift toward home-based healthcare. Meanwhile, emergency services and sports & fitness represent emerging niches. Emergency responders are increasingly adopting portable systems for their ability to provide immediate oxygen in critical scenarios. The sports and fitness segment is attracting attention as athletes and health-conscious individuals explore oxygen therapy for enhanced recovery and performance. By Distribution Channel: Online and Offline Distribution is evolving with the growing importance of online retail channels, especially post-pandemic. Online platforms offer wider reach, consumer education, and price transparency, making them a preferred option for many users. Nevertheless, offline distribution through pharmacies, medical equipment stores, and hospital networks still holds substantial market share, especially in regions where e-commerce penetration remains limited. Market Segmentation Product Type Continuous Flow Oxygenerators Pulse Dose Oxygenerators Technology Molecular Sieves Membrane Separation End-User Hospitals Home Care Emergency Services Sports and Fitness Distribution Channel Online Distribution Offline Distribution Application Medical Recreational Industrial Browse full Report - Regional Insights North America North America leads the global portable oxygenerator market, capturing around 40% of the total revenue in 2024. This is attributed to the presence of advanced healthcare infrastructure, high prevalence of respiratory conditions, and proactive government policies promoting home healthcare. Technological innovation and consumer awareness are also more mature in this region. Europe Europe holds a significant share of approximately 30%, fueled by increasing awareness around oxygen therapy, a rising elderly population, and favorable reimbursement policies. The European market is expected to grow at a CAGR of about 5% through 2034. Asia-Pacific The Asia-Pacific region is witnessing rapid market expansion, with a projected CAGR of 7%. Key drivers include rising air pollution, increasing healthcare investments, and a large patient population base. Countries like China, India, and Japan are driving demand through both public and private sector healthcare initiatives. Latin America, Middle East, and Africa Emerging markets in Latin America and the Middle East & Africa offer considerable growth opportunities. Challenges such as limited infrastructure and inconsistent regulations exist, but these are gradually being addressed through public-private partnerships and increasing medical awareness. Cost-effective product offerings tailored for local needs could unlock growth in these regions. Competitive Landscape The competitive environment is characterized by innovation, partnerships, and geographical expansion. Key players in the industry include: Philips Respironics Inogen, Inc. AirSep Corporation ResMed Chart Industries DeVilbiss Healthcare Caire Inc. Oxymat A/S Invacare Corporation Companies are increasingly investing in product development and acquisitions to enhance their market position. Strategic alliances with local distributors are also being leveraged to improve regional penetration. Recent Market Developments Philips Respironics launched the SimplyGo Mini+ in January 2023, featuring longer battery life and improved mobility, addressing user demand for highly portable medical-grade solutions. In March 2023, Inogen, Inc. acquired a technology firm specializing in oxygen delivery innovation, aiming to boost its technological edge and expand its product line. ResMed, in July 2023, announced its expansion into the Asia-Pacific market, targeting India and Southeast Asia to capitalize on increasing demand and investment in healthcare. AirSep Corporation introduced a new portable oxygen concentrator in September 2023 with reduced power consumption and enhanced oxygen purity, appealing to cost-conscious and eco-friendly buyers. Chart Industries entered a strategic partnership in India in October 2023 to expand its distribution network and cater to rising local demand. This report is also available in the following languages : Japanese (ポータブル酸素発生器市場), Korean (휴대용 산소 발생기 시장), Chinese (便携式制氧机市场), French (Marché des oxygénateurs portables), German (Markt für tragbare Sauerstoffgeneratoren), and Italian (Mercato degli ossigeneratori portatili), etc. Request Sample Pages: More Research Finding – Indoleamine 2,3 Dioxygenase 1 IDO1 ELISA Kit Market The market for Indoleamine 2,3 Dioxygenase 1 (IDO1) ELISA kits is poised for significant growth, with a current estimated value of approximately USD 150 million in 2024. This market is projected to reach around USD 300 million by 2034, reflecting increasing interest in immunotherapy and its applications in cancer treatment and autoimmune disorders. The anticipated CAGR for the period 2025–2034 is approximately 7%. Indoleamine 2,3 Dioxygenase 1 Antibody Market The Indoleamine 2,3 Dioxygenase 1 (IDO1) antibody market is poised for significant growth, projected to reach a value of approximately $1.2 billion in 2024. The market is expected to expand at a Compound Annual Growth Rate (CAGR) of 15% from 2025 to 2034, potentially reaching around $5.0 billion by the end of the forecast period. Obesity Hypoventilation Syndrome Treatment Market The Obesity Hypoventilation Syndrome (OHS) treatment market is projected to reach a value of approximately $1.2 billion in 2024 and is expected to grow significantly, with a forecasted market value of around $2.5 billion by 2034. This growth represents a Compound Annual Growth Rate (CAGR) of approximately 7.6% during the forecast period from 2025 to 2034. Medical Gas Making Equipment Market The global medical gas making equipment market is valued at approximately $1.2 billion, driven by the rising demand for medical gases in hospitals and the growth of home healthcare services. The projected market value is expected to reach around $2.3 billion by 2034, reflecting robust growth opportunities in emerging markets and innovations in technology. Hospital Centralized Oxygen Supply System Market The global market for Hospital Centralized Oxygen Supply Systems is valued at approximately $2.5 billion, with expectations to reach about $4.8 billion by 2034. This growth trajectory indicates a strong Compound Annual Growth Rate (CAGR) of around 7.2% during the forecast period of 2025–2034. Portable Oxygenerator Market The global portable oxygenerator market is valued at approximately USD 2.1 billion in 2024 and is projected to reach around USD 4.5 billion by 2034, reflecting a robust CAGR of about 8.0% during the forecast period from 2025 to 2034. Physical & Chemical Sensors for Water Market The global market for physical and chemical sensors for water is projected to reach approximately $5.2 billion in 2024, fueled by increasing concerns over water quality and pollution management. The market is expected to expand significantly, with a projected value of $9.1 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period from 2025 to 2034. Chemical Oxygen Demand COD Analyzers Market The global market for Chemical Oxygen Demand (COD) analyzers is valued at approximately $300 million in 2024. With increasing regulatory pressure for water quality monitoring and enhanced environmental protection standards, the market is projected to reach around $500 million by 2034. This represents a Compound Annual Growth Rate (CAGR) of about 5.2% during the forecast period from 2025 to 2034. Steel Wire Rod Market The global steel wire rod market is projected to be valued at approximately $150 billion in 2024, with expectations to reach around $220 billion by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of 4.0% during the forecast period of 2025 to 2034. Therapeutic Respiratory Devices Market The global market for therapeutic respiratory devices is estimated to reach approximately $31 billion in 2024, driven by increasing prevalence of respiratory diseases and rising healthcare expenditure. The market is projected to grow at a compound annual growth rate (CAGR) of around 7% from 2025 to 2034, anticipating a value of nearly $63 billion by the end of the forecast period. Cryogenic Submerged Electric Motor Pump Market The global market for cryogenic submerged electric motor pump systems is projected to be valued at approximately $2.1 billion in 2024, with expectations of reaching around $3.9 billion by 2034. This growth represents a Compound Annual Growth Rate (CAGR) of about 6.5% during the forecast period of 2025 to 2034. Extracorporeal Membrane Oxygenation ECMO Service Market The global Extracorporeal Membrane Oxygenation (ECMO) market is anticipated to reach a value of approximately $3.2 billion in 2024, driven by increasing prevalence of respiratory and cardiac illnesses, advancements in ECMO technologies, and a growing aging population. From 2025 to 2034, the market is projected to expand significantly, reaching an estimated $5.8 billion, reflecting a robust Compound Annual Growth Rate (CAGR) of around 7.2%. Oxygen Supply System to Hospitals Market the global oxygen supply system market for hospitals is valued at approximately $5.2 billion, reflecting a robust demand amid ongoing health challenges. The market is projected to reach about $8.4 billion by 2034, indicating significant growth over the next decade. This results in a Compound Annual Growth Rate (CAGR) of around 4.7% from 2025 to 2034. SBQ Steel Market The global Special Bar Quality (SBQ) steel market is valued at approximately $20 billion, with expectations of reaching $30 billion by 2034. This growth is projected at a compound annual growth rate (CAGR) of around 5.5% during the forecast period from 2025 to 2034. The market is currently characterized by robust demand across various sectors, particularly automotive and construction, driven by the rising need for high-strength materials. High Purity Oxygen Market The global high purity oxygen market was valued at approximately $6.2 billion in 2024, driven by applications in healthcare, steel manufacturing, and electronics. With increasing demand for high-purity oxygen in medical applications, particularly in respiratory therapies amid rising respiratory diseases, the market is poised for significant growth. The projected market value is expected to reach around $10.5 billion by 2034, indicating a robust expansion trajectory. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
OPINION - The City wanted Labour to succeed, but the goodwill has been rapidly squandered
In April 2024 the boardrooms in the City of London and some from industry and commerce were buzzing with excitement at the prospect of Labour taking over from a rudderless Conservative administration. In the previous four years, the Tory government never recovered from the damage inflicted by Covid, coupled with indolent leadership from three Prime Ministers in double quick time. This was Labour's time. The mood was upbeat. 'Fear initially knocked at the door, faith answered; no one was there.' The smoked salmon bagel breakfasts hosted for combinations from Messrs Starmer, Reeves, Reynolds and Siddiq were very encouraging. The PM in waiting and his colleagues had charmingly reassured their board table hosts that Labour was the party for business and growth. Business had nothing to worry about. Labour was very much 'on-side' and knew unequivocally that to achieve growth, incentives to invest must be encouraged. All Labour's ducks seemed to be set up cleverly in a row. It took only six months for the reassured to start having considerable doubts, such was the damage inflicted on business by an increase on employers' share of National Insurance Contributions. There were also very little in the way of incentives to encourage inward investment, despite the formation of the National Wealth Fund and the British Business Bank to support Labour's ambitious plans for massive infrastructure projects. Confidence in the new government started to fall like a stone. Global investors seemed very reluctant to support some of our aspiring SMES, especially the fin-tech operations. Many market activists have blamed Brexit, which had only been delivered in name only. What was so frustrating was the ineptness of the Conservatives, which failed to deliver a gold-plated certainty – the increased prosperity of the 'City' – the quintessential cash cow. The financial sector in the UK was already delivering £75 billion of revenue per annum to the HM Treasury's coffers and there could have been so much more to come. The previous Government failed to capitalise on the value of the City. Brexit should have been a 'slam-dunk' for the City. Sadly, no exciting tax incentives for companies to set up in the UK were put into place. Regulation was far too onerous and cumbersome. Also, if the UK aspired to be the world's leading financial centre, charging stamp duty on trading shares was unrealistic financial nonsense. Also spiteful legislation towards 'non-doms' just exacerbates the negative perception of the UK's ability to create growth. The '80's were the halcyon years for the City, triggered by the abolition of exchange controls in 1979, followed up in 1986 by 'Big Bang', which saw international investment banks such as Goldman Sachs, JP Morgan, Deutsche Bank and UBS rub shoulders and then usurp many of the grand old merchant banks of the day such as SG Warburg, Morgan Grenfell, Schroders, Samuel Montagu and Barclays Capital. The introduction of the LIFFE futures market in 1984 and the explosion of derivative trading triggered the expansion of capital markets and a tsunami of IPOS and privatisations. London still remains a major financial hub. However, there is some alarming unappetising data to reckon with. In 2007, the UK had 252 Initial Public Offerings (IPOs) on the London Stock Exchange. This represented a decrease from the 367 IPOs the previous year, with overseas IPOs attracted 86 companies from 22 countries. Last year was a poor year for IPOS, mainly due to a dip in confidence and geopolitical issues – just 17 in total here in London and 18 so far this year. There have been 58 IPOS in New York since January 2025. What is very worrying is that in the last year 88 companies have delisted in London. The delisting started with ARM, which left London supposedly valued at $32 billion, is now valued at $138 billion! Flutter and DarkTrace - fallen to US private equity- plus many others have followed. It is generally acknowledged that US fund managers have access to many more investors and consequently greater liquidity has contributed to a 25% valuation premium there. A lack of confidence and enthusiasm in the UK economy have encouraged moves to New York. Recently, Revolut served notice to establish a new Western Europe HQ in Paris and earlier last week 'Wise' said it will be delisting in London and heading for New York. It is alarming to note that only 4% of the LSE'S annual income is derived from stock exchange business. The rest comes from technology (Refinitiv). The LSE needs to raise its game, as does AIM. Aquis Exchange have hosted 4 IPOS so far this year and the outlook, under fresh ownership of 'Six' looks encouraging. Monzo, Starling Bank, Virgin Atlantic, ASDA and Boots are in the mix of companies that may seek public quotations this year, but much depends on market conditions. Hong Kong's Shein's IPO remains in doubt. If the Government believes in growth, then its emissaries, Business Secretary Jonathan Reynolds, Economc Secretary Emma Reynolds and investment minister Baroness Poppy Gustafsson need to wake up and smell the coffee? Business's risk appetite is at a low ebb. Confidence and sentiment are stagnant. Investors are vital. They must be encouraged with incentives! Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Antigen and Antibody Diagnostics Market to Reach USD 68 Billion by 2034, Driven by 4.6% CAGR Growth
Antigen and Antibody Diagnostics Market Outlook and Forecast to 2034 Luton, Bedfordshire, United Kingdom, June 10, 2025 (GLOBE NEWSWIRE) -- Introduction: A Rapidly Evolving Diagnostic Ecosystem The global antigen and antibody diagnostics market is undergoing a significant transformation driven by rapid technological innovation, rising demand for quick and accurate disease detection, and expanding healthcare accessibility, particularly in emerging economies. Valued at approximately $43 billion in 2024, the market is forecasted to reach $68 billion by 2034, growing at a compound annual growth rate (CAGR) of 4.6% during the forecast period. This expansion is reflective of broader healthcare trends, including the increasing need for point-of-care testing, advancements in artificial intelligence (AI) integration, and growing awareness about early diagnosis and disease monitoring. Download PDF Brochure: Drivers: Technology, Infrastructure, and Global Health Priorities One of the core growth catalysts is the evolution of point-of-care testing (POCT) technologies, which allow medical professionals to obtain results swiftly and accurately, often outside traditional laboratory environments. These innovations have proven vital in remote or resource-constrained regions and during public health emergencies such as the COVID-19 pandemic. The demand for portable, efficient, and user-friendly diagnostic devices has never been higher. Another pivotal driver is the growing prevalence of infectious diseases, including influenza, hepatitis, and emerging viral outbreaks. The urgent need for swift containment and response to such health threats accelerates the demand for antigen and antibody testing tools. Parallelly, global healthcare infrastructure development—especially across Asia-Pacific and parts of Latin America and Africa—continues to boost diagnostic adoption by improving laboratory networks, hospital capacity, and access to essential diagnostic services. Technology Integration: AI Enhancing Precision and Efficiency The integration of artificial intelligence (AI) into diagnostic platforms represents a transformative leap forward. AI-driven tools are increasingly used to enhance the accuracy and efficiency of test results, particularly in large-scale screening programs and high-throughput labs. These intelligent systems reduce human error, optimize workflow, and allow for real-time interpretation of complex data. As AI becomes a more integral part of diagnostics, it is enabling providers to deliver faster, more personalized healthcare services, thereby increasing adoption rates globally. Challenges: Regulatory, Financial, and Operational Hurdles Despite strong growth potential, the antigen and antibody diagnostics sector faces several challenges. Regulatory complexity remains a significant obstacle. Obtaining approval for new diagnostic technologies often involves lengthy, costly, and variable processes depending on the region. Smaller manufacturers may find it difficult to meet these regulatory demands, limiting innovation from emerging players. Moreover, the requirement for significant R&D investment poses a financial burden, especially on startups and mid-sized companies. The costs associated with developing, validating, and scaling new diagnostic tests are high, and coupled with pricing pressures in competitive markets, this can hinder profitability and sustainability. Supply chain vulnerabilities, exposed during the COVID-19 crisis, have also demonstrated how disruptions in raw material sourcing and logistics can delay product availability, strain manufacturing timelines, and escalate costs. Segmentation Overview: Understanding the Market Structure By Product Type Antibodies, particularly monoclonal antibodies, command the largest share (around 55%), playing a critical role in diagnosing cancers, autoimmune disorders, and various infectious diseases. Their precision and reliability make them invaluable tools in both clinical and research settings. Antigens represent approximately 40% of the market and are crucial for detecting pathogens in infections. The growing need for early diagnosis tools has led to a rise in antigen-based POCT devices. Assays and Kits, while making up the remaining 5%, provide essential supporting tools, especially in home diagnostics and research laboratories. By Technology ELISA (Enzyme-Linked Immunosorbent Assay) remains the gold standard in diagnostics, accounting for about 30% of the market due to its high sensitivity in detecting a wide range of diseases. Rapid Tests, with a market share of around 25%, are gaining popularity due to their ease of use and quick results. These are extensively used during health crises for mass screenings. Western Blotting and Lateral Flow Assays hold 10–15% and 20% market shares respectively, primarily used in confirmatory diagnostics for infections and autoimmune conditions. By Application Infectious Disease Diagnostics dominate the application segment, with a 40% market share. The continuous emergence of new pathogens ensures sustained demand. Cancer Diagnostics, leveraging antibody-based biomarker detection, account for 30%, with increasing focus on early detection and personalized treatment pathways. Autoimmune and Cardiovascular Disease Diagnostics are emerging areas, supported by rising incidence and innovations in biomarker research. By End User Hospitals and Diagnostic Laboratories are the principal end users, collectively representing 70% of the market, driven by their scale and resource availability. Research Institutions and POCT Facilities contribute around 15%, a figure expected to rise with increased funding and decentralized testing approaches. By Distribution Channel Direct Sales account for around 60%, preferred for their control and customization benefits. Distributors and Retailers, making up the remaining 40%, are essential in expanding geographic reach, particularly in rural and underserved markets. Browse full Report - Market Segmentation By Product Type Antigens Antibodies Other related products (e.g., assays, kits) By Technology ELISA Technology Rapid Tests Western Blotting Lateral Flow Assays By Application Infectious Diseases Cancer Diagnostics Autoimmune Disorders Cardiovascular Diseases Other Applications By End User Hospitals Diagnostic Laboratories Research Institutions Point-of-Care Testing (POCT) Locations By Distribution Channel Direct Sales Distributors and Retailers By Geography North America Europe Asia Pacific Latin America Middle East & Africa Regional Insights: Global Distribution and Growth Potential North America leads the global market with a 45% revenue share in 2024, thanks to a well-established healthcare system, strong regulatory frameworks, and high R&D expenditure. Europe follows, holding 30%, with a CAGR of 6.5% projected. The region benefits from collaborative research efforts, public health initiatives, and advanced diagnostic technologies. Asia-Pacific is the fastest-growing region, forecasted to grow at 8% CAGR through 2034. Rapid urbanization, rising middle-class incomes, and expanded healthcare access in countries like India and China are fueling market growth. Latin America and Middle East & Africa, while smaller in share (around 5% combined), offer high growth potential as investments in healthcare infrastructure and disease surveillance increase. Key Competitors Roche Diagnostics Abbott Laboratories Siemens Healthineers Thermo Fisher Scientific bioMérieux Ortho Clinical Diagnostics BD (Becton, Dickinson and Company) DiaSorin Hologic PerkinElmer Agilent Technologies Genomic Health (a part of Exact Sciences) Mindray Fujirebio Lonza Group Buy Now: Competitive Landscape: Strategic Moves Reshaping the Market Leading players such as Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Thermo Fisher Scientific dominate the market through innovation, acquisitions, and global outreach. Company Name: Roche Diagnostics Month & Year: September 2023 Type of Development: Product Launch Detailed Analysis: Roche Diagnostics launched a new high-throughput antigen testing platform aimed at enhancing the efficiency of diagnostic testing in laboratories. This development is significant as it responds to the ongoing global demand for rapid and accurate diagnostics, particularly post-pandemic. The new platform promises improved sensitivity and specificity in detecting viral infections, thus providing healthcare professionals with reliable results faster. The introduction of such technology is likely to set new standards in the market, potentially pressuring competitors to innovate more aggressively. This could shift competitive dynamics, as companies pivot to ensure their products are equally adept at meeting these emerging standards of testing reliability and speed, leading to an increased focus on R&D investment across the industry. Company Name: Abbott Laboratories Month & Year: August 2023 Type of Development: Acquisition Detailed Analysis: Abbott Laboratories announced its acquisition of a leading biotech firm specializing in antibody development for diagnostic applications. This acquisition aligns with Abbott's strategic goal of enhancing its diagnostic portfolio. The integration of advanced biotechnology and proprietary methods from the acquired firm is expected to bolster Abbott's capabilities in antibody-based diagnostics. This move could influence market dynamics by consolidating Abbott's position as a leader in the diagnostic space, thus challenging other major players such as Roche and Siemens. With enhanced capabilities, Abbott may be able to offer more sophisticated testing solutions that can penetrate existing markets and attract new clientele, thereby reshaping consumer preferences and competitive threats in the industry. Company Name: Siemens Healthineers Month & Year: July 2023 Type of Development: Regulatory Approval Detailed Analysis: Siemens Healthineers received regulatory approval for its innovative antibody testing solution designed for autoimmune disorders. This marked a significant milestone for the company, as it expands its offerings in a specialized market segment. The approval not only reflects Siemens' commitment to innovation in diagnostics but also enhances its competitive edge against rivals trying to penetrate the growing autoimmune diagnostics market. The acceptance of this product can lead to increased market share for Siemens as healthcare providers increasingly focus on accurate diagnostic tools to improve patient outcomes. This development may incite competitive shifts, prompting other companies to expedite their R&D and seek similar regulatory approvals to maintain their market positions. Company Name: Hologic Month & Year: June 2023 Type of Development: Partnership Detailed Analysis: Hologic entered into a strategic partnership with a leading software company to develop advanced AI-driven diagnostic platforms. This partnership intends to combine Hologic's diagnostic expertise with cutting-edge AI technology to enhance diagnostic accuracy and operational efficiency. The significance of this partnership lies in its potential to revolutionize how diagnostic data is interpreted, shifting the industry towards more personalized medicine. As AI tools become integrated into diagnostic workflows, there may be a notable change in how healthcare providers make clinical decisions. This could create a competitive advantage for Hologic, attracting healthcare providers eager to leverage AI technologies, steering the market towards more technologically advanced solutions. Company Name: PerkinElmer Month & Year: May 2023 Type of Development: Expansion Detailed Analysis: PerkinElmer announced the expansion of its manufacturing facility to enhance production capabilities for antibodies used in various diagnostic applications. This expansion comes as a direct response to the increasing global demand for high-quality diagnostic tools, spurred by heightened awareness of preventive healthcare. The facility's upgrade aims to double the production output, thereby streamlining supply chains and reducing lead times for customers. This proactive approach positions PerkinElmer as a major player capable of meeting market demand amidst rising competition. The strategic expansion not only solidifies PerkinElmer's commitment to quality and accessibility in diagnostics but also signals broader market trends towards scalability and responsiveness in manufacturing processes within the diagnostic industry. This report is also available in the following languages : Japanese (診断市場向け抗原・抗体), Korean (진단용 항원 및 항체 시장), Chinese (诊断市场用抗原和抗体), French (Antigènes et anticorps pour le marché du diagnostic), German (Antigene und Antikörper für den Diagnostikmarkt), and Italian (Antigene e anticorpi per il mercato diagnostico), etc. Request Sample Pages: More Research Finding – Glow Cell Assay Reagents Market The global Glow Cell Assay Reagents market is valued at approximately $980 million in 2024, with a projected market value reaching around $1.95 billion by 2034. This growth trajectory reflects a robust Compound Annual Growth Rate (CAGR) of 7.2% during the forecast period from 2025 to 2034. Microbubble Contrast Media Market The global microbubble contrast media market is projected to reach approximately $650 million by the end of 2024, driven by the growing demand for enhanced imaging techniques in diagnostic procedures. The market is expected to witness substantial growth over the forecast period from 2025 to 2034, with a projected market value of around $1.2 billion by 2034. Cancer Nanomedicine Market The cancer nanomedicine market is valued at approximately $72 billion in 2024, with an anticipated growth trajectory that will elevate its market value to around $150 billion by 2034. This reflects a Compound Annual Growth Rate (CAGR) of approximately 7.6% during the forecast period from 2025 to 2034. Cycloplegic Agents Market The global cycloplegic agents market is valued at approximately $1.2 billion in 2024, with a forecasted growth trajectory anticipated to reach around $1.8 billion by 2034. This translates to a robust Compound Annual Growth Rate (CAGR) of approximately 4.1% for the period from 2025 to 2034. Gastroesophageal Reflux Therapeutic Instrument Market The gastroesophageal reflux (GER) therapeutic instrument market is projected to reach a value of approximately $3.5 billion in 2024, driven by increasing prevalence of gastroesophageal reflux disease (GERD) and advancements in therapeutic technologies. Over the forecast period from 2025 to 2034, this market is expected to grow at a robust Compound Annual Growth Rate (CAGR) of 6.2%, projecting a market value of about $6.5 billion by 2034. Mobile G-arm Market The global mobile G-arm market is valued at approximately $1.5 billion in 2024, driven by the increasing adoption of advanced imaging technologies in surgical and diagnostic procedures. The market is expected to reach around $2.8 billion by 2034, reflecting a compound annual growth rate (CAGR) of 6.7% during the forecast period from 2025 to 2034. Sports Medicine Consumables Market The global sports medicine consumables market is valued at approximately $6.5 billion in 2024, with projections indicating significant growth, potentially reaching $11.2 billion by 2034. This growth trajectory translates to a Compound Annual Growth Rate (CAGR) of around 6.5% over the forecast period from 2025 to 2034. Full Automatic Nucleic Acid Detection Analyzer Market The global market for Full Automatic Nucleic Acid Detection Analyzers is poised to reach an estimated value of $2.5 billion in 2024, driven by increasing demand for precise diagnostic tools in healthcare. The market is projected to expand significantly over the forecast period from 2025 to 2034, with a predicted market value of approximately $4.8 billion. This growth represents a Compound Annual Growth Rate (CAGR) of around 8.4%. Fetal Magnetic Resonance Imaging System Market The global fetal magnetic resonance imaging (fMRI) system market is valued at approximately $150 million. This innovative imaging technology is essential for prenatal diagnostics, providing non-invasive insights into fetal development. The market is projected to reach around $350 million by 2034, driven by advancements in MRI technology and increasing awareness of prenatal health. Doppler Diagnosis System Market The global market for Doppler diagnosis systems is valued at approximately $1.2 billion in 2024, driven by advancements in diagnostic imaging technology and increasing demand for non-invasive procedures. Looking ahead, the market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.5%, potentially reaching around $2.2 billion by 2034. Vacuum Assisted Biopsy Equipment Market The global vacuum-assisted biopsy (VAB) equipment market is valued at approximately $1.2 billion in 2024, with projections indicating a market growth to around $2.5 billion by 2034. This represents a robust Compound Annual Growth Rate (CAGR) of approximately 7.7% during the forecast period from 2025 to 2034. Urodynamic Analyzer Market The global urodynamic analyzer market is valued at approximately $450 million, with a robust growth trajectory anticipated over the next decade. Projections indicate that the market will reach about $800 million by 2034, reflecting a Compound Annual Growth Rate (CAGR) of roughly 6.2% from 2025 to 2034. Urodynamic Manometer Market The global urodynamic manometer market is estimated to reach a value of approximately $350 million in 2024, driven by increasing prevalence of urinary disorders and a rising geriatric population that requires reliable diagnostic tools. The market is projected to grow significantly, with a forecasted value of around $550 million by 2034, reflecting a Compound Annual Growth Rate (CAGR) of 4.7% during the period from 2025 to 2034. Disposable Uterine Probe Market The disposable uterine probe market is projected to achieve a value of approximately $150 million in 2024, with a robust growth trajectory anticipated through the forecast period of 2025 to 2034, reaching an estimated market value of around $450 million. This represents a Compound Annual Growth Rate (CAGR) of about 12.5%. Disposable Injection Needle for Endoscope Market The disposable injection needle market for endoscopy is valued at approximately $500 million in 2024, driven by an increasing prevalence of gastrointestinal diseases and a growing demand for minimally invasive procedures. The market is projected to reach around $1.2 billion by 2034, reflecting significant opportunities within the healthcare sector as technological advancements improve the efficacy of endoscopic tools. Coagulation Controls Market The global coagulation control market is valued at approximately $3.2 billion in 2024 and is projected to reach around $5.8 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of about 6.5% during the forecast period from 2025 to 2034. Iomeprol Injection Market The global market for Iomeprol Injection is valued at approximately $320 million, driven by increasing demand for advanced imaging diagnostics and enhanced patient safety measures. The market is projected to expand at a CAGR of 6.5% from 2025 to 2034, potentially reaching around $651 million by the end of the forecast period. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
